FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
News|Articles|July 2, 2004
- Pharmaceutical Technology-07-02-2004
- Volume 28
- Issue 7
The LR Method in Critical Areas: Airflow Patterns and the Design of Aseptic Interventions
Author(s)Berit Reinmuller, PhD
The limitation-of-risks (LR) method can be used as an engineering tool in risk assessment work for the identification, minimization, and evaluation of potential airborne risks, and for the identification of adequate monitoring points.
Advertisement
Articles in this issue
over 22 years ago
3M Drug Delivery Systemsover 22 years ago
AccuRateover 22 years ago
July 2004over 22 years ago
Investors Shy Away from Pharmaceutical Chemicalsover 22 years ago
In the Spotlight-July 2004over 22 years ago
A Stability Program for the Distribution of Drug Productsover 22 years ago
Politics Versus Science in Biomedical Research and DevelopmentAdvertisement
Related to this article
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
NVIDIA’s $250M, five-year compute donation funds UK agentic AI safety research, with implications for how GMP teams validate and govern autonomous AI.
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Nitrosamine Problems and Industry Solutions: PharmTech Explained
2
AAPS PharmSci 360 2026: E&L Standards Harmonization
3
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
4
Formulation and Evaluation of a Sustainable Analgesic Cream Utilizing Renewable Bio-Based Ingredients and Green Chemistry Design Principles
5